Table 12.6a

Immunosuppression Use for Induction, 1995 to 2004

Recipients with Lung Transplants

  Year of Transplant
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Transplants 893 836 948 893 922 977 1,083 1,054 1,099 1,185
With Immunosuppression Info 878 764 931 885 895 950 1,065 1,030 1,088 1,159
Induction Drugs 0.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 23.3% 22.6% 19.5% 13.9% 12.6% 11.9% 8.8% 6.4% 4.9% 5.4%
OKT3 5.2% 3.7% 2.5% 3.5% 3.4% 2.6% 1.0% 0.6% 1.1% 0.5%
Thymoglobulin 0.0% 0.0% 0.0% 0.0% 1.9% 6.0% 5.4% 8.3% 3.0% 3.7%
Zenapax 0.0% 0.0% 0.0% 4.9% 9.6% 14.6% 11.3% 13.7% 15.6% 14.8%
Simulect 0.0% 0.0% 0.0% 0.3% 3.2% 8.3% 12.8% 15.0% 19.6% 22.8%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.9% 3.2%
No Induction Drugs Recorded 71.0% 73.8% 78.2% 77.5% 69.5% 56.9% 61.1% 56.3% 55.9% 50.5%


Source: OPTN/SRTR Data as of May 2, 2005.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.